KRAS and breast cancer: Previous studies have found that in high-grade plasmacytotic ovarian cancer, focal adhesion kinase (FAK) small molecule inhibitors reduce tumor load, inhibit CD155, CD112, and PD-L1 levels on KMF (Kras, Myc, FAK) cells, and prolong host survival when combined with TIGIT-blocking monoclonal antibodies [36]; in breast cancer, the combination of small molecule inhibitors targeting DNA methyltransferases and TIGIT monoclonal antibodies was found to better inhibit tumor metastatic potential [37].